Literature DB >> 24449368

Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study.

Xian-Feng Lin1, Ke-Qing Shi, Jie You, Wen-Yue Liu, Ying-Wan Luo, Fa-Ling Wu, Yong-Ping Chen, Danny Ka-Ho Wong, Man-Fung Yuen, Ming-Hua Zheng.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has been suggested to be a strong risk factor of colorectal benign adenomas and advanced neoplasms. The aim of this large cohort study was to further investigate the prevalence of colorectal malignant neoplasm (CRMN) in patients with NAFLD and determine whether association between NAFLD and CRMN exists. 2,315 community subjects (1,370 males and 945 females) who underwent a routine colonoscopy according to international colorectal cancer screening guideline were recruited. Nature of colorectal lesions determined by biopsy and NAFLD was diagnosed by ultrasound. Binary logistic regression analysis was applied to explore the related associations. Prevalence of CRMN was 29.3% (77/263) in patients with NAFLD, which was significantly higher than 18.0% (369/2,052) in the control group (P<0.05). In addition, malignant neoplasm in NAFLD group occurred more frequently at sigmoid colon than in control group (14.3 vs. 11.9%). The incidence of highly-differentiated colorectal adenocarcinoma in NAFLD group was significantly higher than control group (62.3 vs. 9.8%). Univariate analysis showed that NAFLD had strong association with CRMN (OR 2.043; 95% CI 1.512-2.761; P<0.05). After adjusting for metabolic and other confounding factors, NAFLD remained as an independent risk factor for CRMN (OR 1.868; 95% CI 1.360-2.567; P<0.05). NAFLD was an independent risk factor for CRMN. Sigmoid carcinoma and highly differentiated colorectal adenocarcinoma were more commonly found in NAFLD. (ClinicalTrials.gov number, NCT01657773, website: http://clinicaltrials.gov/ct2/show/NCT01657773?term=zheng+minghua&rank=1 ).

Entities:  

Mesh:

Year:  2014        PMID: 24449368     DOI: 10.1007/s11033-014-3157-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  45 in total

1.  The metabolic syndrome and risk of incident colorectal cancer.

Authors:  Rehana L Ahmed; Kathryn H Schmitz; Kristin E Anderson; Wayne D Rosamond; Aaron R Folsom
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

2.  [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration].

Authors:  Jan P Vandenbroucke; Erik Von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  Gac Sanit       Date:  2009-02-26       Impact factor: 2.139

3.  American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008.

Authors:  Oralia Garcia Dominic; Thomas McGarrity; Mark Dignan; Eugene J Lengerich
Journal:  Am J Gastroenterol       Date:  2009-10       Impact factor: 10.864

Review 4.  Leptin: the prototypic adipocytokine and its role in NAFLD.

Authors:  Claudio Procaccini; Mario Galgani; Veronica De Rosa; Fortunata Carbone; Claudia La Rocca; Giusy Ranucci; Raffaele Iorio; Giuseppe Matarese
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

5.  Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia.

Authors:  A Stadlmayr; E Aigner; B Steger; L Scharinger; D Lederer; A Mayr; M Strasser; E Brunner; A Heuberger; F Hohla; J Steinwendner; W Patsch; C Datz
Journal:  J Intern Med       Date:  2011-04-25       Impact factor: 8.989

6.  Predictors of colorectal cancer screening participation in the United States.

Authors:  George N Ioannou; Michael K Chapko; Jason A Dominitz
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

7.  High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Steven Woon-Choy Tsang; Tina Fan; Winnie Chiu-Wing Chu; Jean Woo; Anthony Wing-Hung Chan; Paul Cheung-Lung Choi; Angel Mei-Ling Chim; James Yun-Wong Lau; Francis Ka-Leung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  Gut       Date:  2011-02-21       Impact factor: 23.059

8.  Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences.

Authors:  Thomas M Gluecker; C Daniel Johnson; William S Harmsen; Kenneth P Offord; Ann M Harris; Lynn A Wilson; David A Ahlquist
Journal:  Radiology       Date:  2003-05       Impact factor: 11.105

Review 9.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

10.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

View more
  26 in total

1.  Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.

Authors:  Amanda I Phipps; Michael N Passarelli; Andrew T Chan; Tabitha A Harrison; Jihyoun Jeon; Carolyn M Hutter; Sonja I Berndt; Hermann Brenner; Bette J Caan; Peter T Campbell; Jenny Chang-Claude; Stephen J Chanock; Jeremy P Cheadle; Keith R Curtis; David Duggan; David Fisher; Charles S Fuchs; Manish Gala; Edward L Giovannucci; Richard B Hayes; Michael Hoffmeister; Li Hsu; Eric J Jacobs; Lina Jansen; Richard Kaplan; Elisabeth J Kap; Timothy S Maughan; John D Potter; Robert E Schoen; Daniela Seminara; Martha L Slattery; Hannah West; Emily White; Ulrike Peters; Polly A Newcomb
Journal:  Carcinogenesis       Date:  2015-11-19       Impact factor: 4.944

2.  PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.

Authors:  Amanda I Phipps; Dennis J Ahnen; Iona Cheng; Polly A Newcomb; Aung Ko Win; Terrilea Burnett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-20       Impact factor: 4.254

3.  Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis.

Authors:  Wenjin Ding; Jiangao Fan; Jianjun Qin
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)-cause for concern?

Authors:  Matthew J Armstrong; Geoffrey Haydon; Wing-Kin Syn
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

Review 5.  Adenomas - Genetic factors in colorectal cancer prevention.

Authors:  Kycler Witold; Kubiak Anna; Trojanowski Maciej; Janowski Jakub
Journal:  Rep Pract Oncol Radiother       Date:  2018-02-09

6.  Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis.

Authors:  Huafeng Shen; Seth Lipka; Ambuj Kumar; Paul Mustacchia
Journal:  J Gastrointest Oncol       Date:  2014-12

7.  Assessment of hepatic steatosis on contrast enhanced computed tomography in patients with colorectal cancer.

Authors:  Elif Aktas; Metin Uzman; Okan Yildirim; Burcu Sahin; Fatih Buyukcam; Bora Aktas; Baris Yilmaz; Aslihan Mete Yildirim; Sebahat Basyigit; Ozgur Yeniova; Ayse Kefeli; Bilgin Kadri Aribas
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 8.  Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.

Authors:  Naga S Samji; Rajanshu Verma; Sanjaya K Satapathy
Journal:  J Clin Exp Hepatol       Date:  2019-05-16

Review 9.  Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.

Authors:  Jiao-Ya Xu; Zhong-Ping Li; Li Zhang; Guang Ji
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

10.  The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers.

Authors:  Nicolette Veracruz; Bilal Hameed; Sammy Saab; Robert J Wong
Journal:  J Clin Exp Hepatol       Date:  2020-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.